Sir,
Deregulation of hypothalamo-pituitary adrenal axis (HPA) is one of the oldest and most consistent findings in depression. It is now generally accepted that stressful life events and chronic difficulties can trigger the onset of depression in predisposed individuals. Enough is known about the central control of HPA function and its response to stress in the neurobiology of triggering the depression. The stress induces hypercortisolaemia which triggers depression by inducing genomic change. There are two types of corticoid receptors in brain tissue -type I and type II receptors (Reul & De Kloet, 1986) . Under basal conditions Cortisol has very high affinity with 80% occupancy of type I receptors whereas type II receptors are occupied and activated only during stress (Ratka, 1989) . Further, hippocampus is the most vulnerable site for the neurotoxic action of glucocorticoids The glucocorticoid recepters are predominandy present in hippocampal area. Of late, in vivo hippocampal atrophy assessed using magnetic resonance imaging has been correlated with plasma Cortisol levels in depression (Axelson et al., 1993) A related but astonishing fact is that all hormones with weH defined effects on mood (estrogen, progesterone, glucocorticoids and thyroxine) have intraceRuar receptors whereas most other hormones act through membrane receptors. More surprising than this is that these intracellular receptors have two
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aminoacid sequences in common which are thought to bind hormones to specific sequences of DNA and modify the gene transcription (Beato, 1989) . The complex formed by the binding of a steroid with a receptor is translocated into the cell nucleus where it binds to DNA and influences the expression of genes So the activation in depression of the HPA axis involves various steps in producing excess Cortisol and then inducing genomic change. The blockade at each one of them is being targeted to antagonise the effects of stressful life events in producing depression or in the treatment of depression. The therapeutic potential of antiglucocorticoid drugs especially type II receptor antagonists and steroid synthesis inhibitors have been explored with encouraging results in patients with mood disorders (Mitchell & O'Keanne, 1998) . Mr. PCJ aged about 44 years, a cterk in NCC came to consult in June 97 with one year history of decreased interest in family, work & social activities, sleep and appetite. Interview was difficult as he was hard of hearing from both ears. With whatever communication possible by shouting at his right ear, he was found to be depressed, had ideas of hopelessness, worthlessness & a misfit in the present set up. He occasionally had ideas of ending his life.
Reul, J.M.H.M. & Dekloet, E.R. (1986)
He was prescribed Imipramine 75 mg per day, alprazolam 0.5 mg twice daily and advised to see an ENT specialist. He came back after 20 days with a relative and treatment records of his deafness. He had bilateral hearing impairment for last 15 years, more marked on the left side. Clinically he was diagnosed as having "healed otitis media with adhesive otitis media left". Audiogram revealed that patient had severe degree of conductive type of hearing loss in both ears more marked on left side. He was referred to neurosurgeon who advised CT scan head which was not done.
Dejected Mr. PCJ came back having lost all hopes of hearing again. Meanwhile, dosage of imipramine was subsequently increased to 125 mg per day. Over a period of few weeks his depression started lifting up. After 8-10 weeks when he came for review I was surprised to know that he could hear from both the ears. Hearing improved to the extent that he could converse on phone, could sense boiling of water from a distance of 3-4 feet.
Weather this deafness was present to a minimum extent and got increased with depression or there was any relationship between the two cannot be commented upon with any certainty but what is sure that the deafness improved with imipramine.
May be this experience of mine, stimulates few to explore the role of imipramine in treating such type of deafness?
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